

Evidence dossier - Edgewood Management

GetCoattail manager profile: <https://getcoattail.com/manager/edgewood-management> | CIK 0000860561 | Rank #52 of 149 tracked managers by reported 13F value.

Background: Founded: 1974 | HQ: Greenwich, CT | Style: Concentrated large-cap growth, single 22-stock portfolio | Key person: Alan Breed

Background source: <https://dakotafunds.com/edgewood>

1. Latest filing snapshot (as reported)

Period end: 2026-06-30 Filed: 2026-08-13 Reported total value: \$9.7B Positions: 90 Top-10 concentration: 63.4% of reported value.

Ticker	Company	Weight	Reported value
NVDA	Nvidia Corporation	9.46%	\$917M
ASML	Asml Hldg Nv	8.88%	\$861M
AVGO	Broadcom Inc	7.63%	\$740M
AXON	Axon Enterprise Inc	6.50%	\$631M
APH	Amphenol Corp	5.71%	\$554M
SNPS	Synopsys Inc	5.65%	\$548M
V	Visa Inc	5.62%	\$545M
SHOP	Shopify Inc	4.84%	\$469M
LLY	Eli Lilly & Co	4.81%	\$466M
NFLX	Netflix Inc.	4.28%	\$415M

2. Hypothetical 13F-clone results

Window: 2016-11-14 to 2026-10-02 (40 filings). Cumulative: +291.0% CAGR: +14.80% SPY same window: cumulative +316.1%, CAGR +15.52%. Trailing CAGR - 10Y: n/a, 5Y: +0.78%, 3Y: +10.55%, 1Y: -7.27%. Max drawdown (month-end, approximate): -47.0%.

Method (summary): For each Form 13F filing in the history table, the clone takes the positions and weights exactly as disclosed (reported values at the period end). From the filing date until the next filing date, each position earns the return of its dividend-adjusted closing price (Yahoo Finance daily bars; split- and dividend-adjusted). At each new filing the clone rebalances to the newly disclosed weights. Positions that cannot be priced (non-U.S. listings, some recent IPOs and delisted names) are excluded from both the weights and the returns, and the covered share of reported value is stated in this dossier. The benchmark is SPY on the same dividend-adjusted basis over the identical window. Month-end values are used for drawdown and trailing-window statistics and are approximate.

3. Filing history - every clone input

Each row is one SEC Form 13F filing used by the clone. Accession numbers link to the filing index at sec.gov: <https://www.sec.gov/Archives/edgar/data/<CIK>/<accession without dashes>/<accession>-index.htm>

Quarter	Accession no.	Filed	CUSIPs
2016Q3	0001062993-16-012203	2016-11-14	92
2016Q4	0001062993-17-000648	2017-02-10	84
2017Q1	0001062993-17-002400	2017-05-12	81
2017Q2	0001062993-17-003684	2017-08-11	79
2017Q3	0001062993-17-004809	2017-11-13	80
2017Q4	0001062993-18-000655	2018-02-13	82
2018Q1	0001062993-18-002100	2018-05-11	71

2018Q2	0001062993-18-003256	2018-08-10	72
2018Q3	0001062993-18-004541	2018-11-13	73
2018Q4	0001062993-19-000748	2019-02-13	72
2019Q1	0001062993-19-002140	2019-05-13	65
2019Q2	0001062993-19-003286	2019-08-12	64
2019Q3	0001062993-19-004276	2019-11-12	64
2019Q4	0001062993-20-000821	2020-02-14	84
2020Q1	0001062993-20-002315	2020-05-13	79
2020Q2	0001062993-20-003837	2020-08-12	76
2020Q3	0001062993-20-005531	2020-11-12	78
2020Q4	0001062993-21-001296	2021-02-12	81
2021Q1	0001062993-21-004477	2021-05-13	83
2021Q2	0001062993-21-007416	2021-08-12	82
2021Q3	0001062993-21-010652	2021-11-12	84
2021Q4	0001062993-22-003627	2022-02-11	85
2022Q1	0001062993-22-012042	2022-05-11	84
2022Q2	0001062993-22-017792	2022-08-12	77
2022Q3	0001062993-22-021845	2022-11-10	80
2022Q4	0001062993-23-002803	2023-02-13	83
2023Q1	0001062993-23-010890	2023-05-12	83
2023Q2	0001062993-23-016242	2023-08-11	82
2023Q3	0001062993-23-020569	2023-11-13	79
2023Q4	0001062993-24-002887	2024-02-13	79
2024Q1	0001062993-24-010118	2024-05-14	79
2024Q2	0001062993-24-014905	2024-08-13	80
2024Q3	0001062993-24-018802	2024-11-12	78
2024Q4	0001062993-25-002246	2025-02-13	83
2025Q1	0001062993-25-009317	2025-05-14	84
2025Q2	0001062993-25-014249	2025-08-13	83
2025Q3	0001062993-25-016658	2025-11-12	88
2025Q4	0001062993-26-000835	2026-02-12	89
2026Q1	0001062993-26-002623	2026-05-14	87
2026Q2	0001062993-26-004244	2026-08-13	90

4. Coverage and adjustments

Price coverage at the latest filing: 79.0% of reported value is covered by our price history and included in the clone; the rest is excluded (mostly non-U.S. listings, recent IPOs, delisted names).

5. Disclaimer

This document and the associated web profile present a hypothetical replication ("13F clone") of the long U.S. equity positions disclosed on Form 13F. It is not the named fund's actual investment return: Form 13F excludes short positions, bonds, cash, non-U.S. listings, private holdings, leverage and fees, and positions are only observable quarterly, with a filing lag of up to 45 days. Nothing here is investment advice or a recommendation. Past hypothetical performance does not guarantee future results.